The Infectious Disease Pharmacokinetics Laboratory at the University of Florida (IDPL) is focused clinically on the treatment of patients with serious infections, including tuberculosis, HIV, and fungal infections. The IDPL provides therapeutic drug monitoring using Liquid chromatography–mass spectrometry (LC-MS) . Therapeutic drug monitoring (TDM) is a well-established clinical tool, and the IDPL focuses on drug assays that most other clinical labs do not offer. For 25 years, the IDPL has individualized patients’ drug regimens by monitoring serum drug concentrations and interpreting the results. Interpretations are based upon many years of clinical experience with these types of patients, allowing health care practitioners to confidently make dose adjustments.
TDM allows clinicians to assess each patient’s pharmacokinetics (drug absorption, distribution, metabolism, and clearance). TDM also allows clinicians to pull apart complex drug-drug interactions, and to arrive at the needed doses for each drug. Tuberculosis is a major focus of the IDPL, but we also serve patients with serious bacterial and fungal infections, people living with HIV, and those patients who acquire opportunistic infections. We also have considerable experience with patients infected with non-tuberculous mycobacterial (NTM) infections.
Under the direction of Dr. Charles Peloquin, who has over 30 years of clinical experience, the IDPL provides services that are unique in the United States. No other lab offers our array of testing combined with Dr. Peloquin’s personal experience in interpreting the results and his availability for consultation regarding your patients.